Wellbutrin SR, Zyban appeal
Executive Summary
GlaxoSmithKline's appeal of non-infringement rulings for Andrx' generic versions of bupropion products Wellbutrin SR and Zyban will be heard Dec. 2 in D.C. federal appeals court. Miami federal court issued summary judgement of non-infringement Feb. 28. Andrx said blend uniformity issues that prevented FDA approval of bupropion ANDAs have been addressed (1"The Pink Sheet" July 15, p. 7)....